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ABSTRACT 49 
Background: The aim of this pilot study was to measure changes in physical activity levels 50 
(PAL) variables, as well as  sleep duration and efficiency in people with locally advanced rectal 51 
cancer (1) before and after neoadjuvant chemoradiotherapy (CRT) and (2) after participating 52 
in a preoperative 6-week in-hospital exercise training programme, following neoadjuvant CRT 53 
prior to major surgery, compared to a usual care control group.  54 
Methods: We prospectively studied 39 consecutive participants (27 males). All participants 55 
completed standardised neoadjuvant CRT: 23 undertook a 6-week in-hospital exercise training 56 
programme following neoadjuvant CRT. These were compared to 16 contemporaneous non-57 
randomised participants (usual care control group). All participants underwent a continuous 72 58 
h period of PA monitoring by Sensewear biaxial accelerometer at baseline, immediately 59 
following neoadjuvant CRT (week 0), and at week 6 (following the exercise training 60 
programme). 61 
Results: Of 39 recruited participants, 23 out of 23 (exercise) and 10 out of 16 (usual care 62 
control) completed the study. In all participants (n=33), there was a significant reduction from 63 
baseline (pre-CRT) to week 0 (post-CRT) in daily step-count: Median (IQR) 4966 (4435) vs. 64 
3044 (3265); p<0.0001, active energy expenditure (EE) (kcal): 264 (471) vs. 154 (164); 65 
p=0.003, and metabolic equivalent (MET) (1.3 (0.6) vs. 1.2 (0.3); p=0.010). There was a 66 
significant improvement in sleep efficiency (%) between week 0 and week 6 in the exercise 67 
group compared to the usual care control group (80 (13) vs. 78 (15) compared to (69 ((24) vs. 68 
76 (20); P=0.022), as well as in sleep duration and lying down time (p<0.05) while those in 69 
active EE (kcal) (152 (154) vs. 434 (658) compared to (244 (198) vs. 392 (701) or in MET (1.3 70 
(0.4) vs. 1.5 (0.5) compared to (1.1 (0.2) vs. 1.5 (0.5) were also of importance but did not reach 71 
statistical significance (p>0.05).An apparent improvement in daily step-count and overall PAL 72 
in the exercise group was not statistically significant. 73 
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Conclusions: PAL variables, daily step-count, EE and MET significantly reduced following 74 
neoadjuvant CRT in all participants. A 6-week pre-operative in-hospital exercise-training 75 
programme improved sleep efficiency, sleep duration and lying down time when compared to 76 
participants receiving usual-care. 77 
Clinical trial registration: NCT: 01325909 78 
KEYWORDS: Rectal cancer, neoadjuvant cancer treatment, physical activity, exercise, 79 
prehabilitation, surgery 80 
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Background 96 
Cancer treatment reduces physical fitness, which appears to be worse in those receiving surgery 97 
and radiotherapy in combination with chemotherapy than in those receiving radiotherapy or 98 
surgery alone [1]. Changes in fitness are clinically important: neoadjuvant chemo- and 99 
chemoradio-therapy reduce physical fitness, objectively measured using cardiopulmonary 100 
exercise testing (CPET), which is associated with increased in-hospital morbidity following 101 
advanced rectal cancer resection [2] and decreased 1-year overall survival following upper 102 
gastrointestinal cancer resection [3].   103 
Physical fitness is closely connected with physical activity (PA), although relationships of 104 
cause and effect are complex. Remaining physically active during and after cancer treatment 105 
improves cancer-related fatigue, psychological distress, quality of life, as well as overall 106 
survival and reduces the probability of cancer recurrence [4]. Increasing PA following cancer 107 
diagnosis may reduce the risk of cancer-specific death in people with breast and non-metastatic 108 
colorectal cancer [5-6] or death from any cause in non-metastatic colorectal cancer [6]. 109 
Exercise training during chemotherapy has a significant beneficial effect on tumour 110 
progression and chemotherapy efficacy in solid tumours [7].   111 
For people diagnosed with locally advanced rectal cancer [Tumour, Node, Metastasis (TNM) 112 
stage >T3N+ magnetic resonance imaging (MRI) identified circumferential resection margin 113 
threatened cancer], the standard treatment is neoadjuvant chemoradiotherapy (CRT) followed 114 
by surgery [8-9]. The aim of this pilot study was to measure changes in daily PAL in people 115 
with locally advanced rectal cancer scheduled to undergo neoadjuvant CRT followed by 116 
surgical resection with a curative intent. We aimed to evaluate changes in daily step-count and 117 
overall PAL pre- and post- neoadjuvant CRT in all participants in an attempt to quantify the 118 
impact of neoadjuvant CRT on PAL. We also aimed to evaluate changes in daily step-count 119 
(number of steps taken) and overall PAL at the start and end of a pre-operative 6-week in-120 
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hospital exercise training programme, commenced after completion of neoadjuvant CRT, 121 
comparing changes with those observed in a usual care control group (no formal exercise 122 
intervention). Exploratory aims included observing changes in other PAL variables such as: 123 
total (EE for daily-living) and active EE (PA-induced EE)PA duration; lying down time; sleep 124 
duration and efficiency; and metabolic equivalent (MET) (intensity of PA) in all participants 125 
following neoadjuvant CRT and compare changes in the exercise group compared to the usual 126 
care control group.  127 
 128 
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Methods 143 
Participants and study design 144 
This prospective pilot, non-randomised, parallel group, interventional controlled trial was a 145 
nested study of a clinical trial [10]. This pilot study was approved by the North West Liverpool 146 
East Research and Ethics Committee (11/H1002/12) and registered with clinicaltrials.gov 147 
(NCT01325909). Written informed consent was obtained from all participants.  We recruited 148 
consecutive participants between March 2011 and February 2014 referred to the Colorectal 149 
Multi-Disciplinary Team, aged ≥18 year, with locally advanced (MRI-defined) circumferential 150 
resection margin threatened, operable rectal cancer, undergoing standardised neoadjuvant CRT 151 
with no distant metastasis and with WHO performance status <2 [11] (categorised between 0 152 
(fully active) to 4 (completely disabled, cannot carry out self-care: totally confined to bed or 153 
chair). Exclusion criteria were: inability to give informed consent; non-resectable disease; 154 
inability to perform CPET or bicycle exercise due to lower limb dysfunction; and participants 155 
who declined surgery or neoadjuvant CRT or who received non-standard neoadjuvant CRT. 156 
After completing neoadjuvant CRT, participants were allocated to the exercise training group 157 
by default. If unable to commit to the exercise schedule (or living >15 miles from the hospital), 158 
they were asked to act as contemporaneously-recruited controls (no formal exercise 159 
intervention) with the same PA monitoring follow-up.  Participant characteristics such as age; 160 
gender; past medical history; ASA score (the ASA score is a subjective assessment of patients 161 
overall health, categorised into 5 classes: I (healthy fit patient) to V (patient who is not expected 162 
to live 24 hours without surgery); and WHO status were collected at baseline visit.  163 
All participants underwent a continuous 72 h period of PA monitoring using Sensewear biaxial 164 
accelerometer (Figure 1). PAL was measured during weekdays at baseline (2 weeks before 165 
neoadjuvant CRT), immediately following neoadjuvant CRT (week 0) and at week 3 and week 166 
6. Participants in the exercise training group undertook a 6-week supervised in-hospital 167 
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exercise training programme (3 sessions per week). The exercise training intensities were 168 
responsive to each individual CPET at week 0 and week 3 (informed and altered according to 169 
measured work rates at oxygen uptake at lactate threshold and at peak exercise). Exercise 170 
training consisted of 40 min (including 5 min warm-up and 5 min cool-down) of interval 171 
training on an electromagnetically braked cycle ergometer (Optibike Ergoline GmbH, 172 
Germany). The interval-training programme consisted of alternating moderate (80% of work 173 
rate at oxygen uptake at lactate threshold – 4 by 3 min intervals) to severe (50% of the 174 
difference in work rates between oxygen uptake at peak and lactate threshold- 4 by 2 min 175 
intervals) intensities (total 20 min) for the first two sessions. This was then increased to 40 min 176 
(6×3 min intervals at moderate intensity and 6×2 min intervals at severe intensity). The exercise 177 
training protocol and procedures are described elsewhere [10].  178 
TNM staging involved flexible sigmoidoscopy for histological diagnosis, colonoscopy, chest, 179 
abdomen, and pelvis computer-aided tomography (CT), and 1.5 T pelvic magnetic resonance 180 
imaging (MRI). All participants underwent 5 weeks neoadjuvant CRT. Standardised 181 
radiotherapy consisted of 45 Gy in 25 fractions on weekdays using a 3D conformal technique 182 
with CT guidance. Oral capecitabine (825 mg m-2) was given twice daily on radiotherapy days. 183 
No participants received brachytherapy.  At 9 weeks post-neoadjuvant CRT, participants were 184 
restaged using chest, abdomen, and pelvic CT and pelvic MRI. The colorectal Multi-185 
Disciplinary Team was blind to PAL results and participant allocation.  186 
Measurements 187 
Daily PAL was measured in all participants using a multi-sensor accelerometer (SenseWear 188 
Pro® armband; BodyMedia, Inc., Pittsburgh, PADL, USA). The SenseWear Amrband Pro is a 189 
reliable estimation of resting EE and provides useful information on daily EE when compared 190 
to indirect calorimetry (cancer patients) [12] and reasonable agreement on daily EE when 191 
compared with doubly labelled water (free living-adults) [13]. The PA accelerometer was worn 192 
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on the upper right arm continuously for 3 consecutive weekdays (except when bathing). 193 
Participants in the exercise-training group removed the PA monitor during in-hospital exercise 194 
training sessions.  195 
The armband estimates energy expenditure (EE) using measurements from a biaxial 196 
accelerometer and sensors that quantify galvanic skin response, heat flux and skin temperature 197 
The device records and reports daily movement: total and active EE; PA duration; number of 198 
steps; lying down time; average MET; sleep duration and efficiency (number of minutes of 199 
sleep divided by number of minutes in bed). The Sensewear Pro can distinguish between lying 200 
down and sleep time by using algorithms that detect the characteristics combination of 201 
orientation, motion, temperature and skin conductivity with each state. 202 
Statistical methods 203 
This was a nested study of a clinical trial, which was powered to detect changes in objectively 204 
measured physical fitness [10]. Therefore no a priori formal power calculation was undertaken 205 
for such a PA pilot study. 206 
Continuous variables are reported as mean (range), mean (SD) or median and inter-quartile 207 
range (IQR), depending on distribution, and categorical variables as frequency (%). The 208 
Shapiro-Wilk test for normality of distributions was applied. Descriptive statistics and 209 
univariate statistical comparisons of patient characteristics between the groups were 210 
undertaken: for continuous variables, a two- sample t-test when relevant distributional 211 
assumptions were met and the Mann–Whitney U-test otherwise; for categorical variables, 2 212 
tests or, when cell counts were insufficient, Fisher’s exact test. 213 
Generalized linear mixed models, with a repeated effect for the comparison between the 214 
consecutive visits, were used to obtain restricted maximum likelihood (REML) solutions with 215 
an unstructured type of the covariance matrix for all or selected measurements in the two 216 
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groups. Least square means with 95% CIs were obtained.  P<0.05 was taken as statistically 217 
significant. All analyses were performed with the statistical software IBM SPSS Statistics 218 
Ver.22 (IBM Corporation, Armonk, NY, USA). 219 
Results 220 
A total of 39 participants were recruited of whom 23 (exercise group) and 10 (usual care control 221 
group) completed the study (6 participants dropped out of the usual care control group: 4 before 222 
baseline measurements and 2 during the study). There were significant baseline differences 223 
between groups in age, ASA and WHO performance status: the usual care control group were 224 
older with poorer subjective performance (Table 1). Further details of participant 225 
characteristics are reported elsewhere [10].  226 
There was a significant reduction in daily step-count between pre neoadjuvant CRT (baseline) 227 
and post neoadjuvant CRT (week 0) in all participants (4966 (4435) vs. 3044 (3265); P<0.0001), 228 
active EE (kcal) (264 (471) vs. 154 (164); P<0.005), and MET (1.3 (0.6) vs. 1.2 (0.3) P<0.05; 229 
table 2)(Supplementary Table 1 shows overall PAL as mean (SD) and median and inter-quartile 230 
range (IQR).  Following the 6-week exercise intervention, the exercise group compared to the 231 
usual care control group showed significant improvements in sleep efficiency (%) (78 (13) vs. 232 
80 (15) compared to(69 (24) vs. 76 (20); P=0.022), sleep duration (min) (190 (269) vs. 369 (81) 233 
compared to (265 (315) vs. 299 (39); P=0.028) and lying down time (min) (360 (352) vs. 47 234 
(476) compared to (541 (360) vs. 341 (372); P=0.029, table 3) (Supplementary Table 2 shows 235 
overall PAL data as mean (SD) and median and inter-quartile range (IQR). Note: (1) the 236 
exercise training group took the PA monitors off for the duration of each in-hospital exercise 237 
session (120 min/week x 6 weeks): (2) sleep efficiency data is presented in only seven 238 
participants in the exercise intervention and usual care control group: this is due to an upgrade 239 
in software during data collection. 240 
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Table 1 Characteristics of patients scheduled for neoadjuvant cancer treatment and surgery 241 
 242 
 Exercise (n=23) Control (n=10) P value 
 
Age (yr)* 
 
64 (45-82) 
 
72 (62-84) 
 
0.015 
 
Gender M:F (%) 
 
15 (65): 8 (35) 
 
8 (80): 2(20) 
 
0.710 
 
Past medical history+ 
Heart failure 
Diabetes 
Ischaemic heart disease 
Cerebrovascular disease 
 
10 (44) 
3 (13) 
2 (9) 
5 (22) 
0 
 
5 (50) 
1 (10) 
1 (10) 
3 (30) 
0 
 
0.617 
 
 
 
ASA± 
I 
II 
III 
 
 
11 (48) 
10 (44) 
2 (9) 
 
 
0 
9 (90) 
1 (10) 
 
0.003 
 
WHO performance status± 
0 
1 
2 
 
 
18 (78) 
5 (22) 
0 
 
 
0 
9 (90) 
1 (10) 
 
 0.035 
Values presented as mean (range). * P<0.05 was taken as statistically significant.  243 
+Frequencies with percentages in parentheses, smoking status assessed as currently smoking: yes (1) vs no (0); 244 
±number of patients (%) WHO performance status and ASA physical status. Participants who dropped out of the 245 
study are not included in participant characteristics. 246 
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Table 2 Pre- and Post- Neoadjuvant CRT physical activity variables 247 
 248 
Physical Activity Variables Pre neoadjuvant CRT 
 
Post neoadjuvant CRT  
 
Change, % Change 
 
P value 
Step count (steps/day) * 
Exercise (n=23) 
Usual care control (n=10) 
   Overall (n=33) 
 
5705.3 (3746) 
3701.5 (3569) 
4966 (4435) 
 
3723 (2867) 
2274 (3690) 
3044.2 (3265) 
 
-2755 (4152), -44 (20) 
-4 (2600), -0.1 (78) 
 
 
 
<0.0001 
MET* 
Exercise (n=23) 
Usual care control (n=10) 
   Overall (n=33) 
 
1.4 (0.5) 
1.3 (0.9) 
1.3 (0.6) 
 
1.3 (0.4) 
1.1 (0.2) 
1.2 (0.3) 
 
-0.03 (0.3), -2.3 (15) 
-0.1 (0.3), -8 (14) 
 
 
 
0.010 
Active EE (kcal/day) * 
Exercise (n=23) 
Usual care control (n=10) 
   Overall (n=33) 
 
229 (482.3) 
354 (443.5) 
264.3 (471.3) 
 
152 (153.7) 
244.3 (198.3) 
154 (163.9) 
 
-115 (499), -30 (93) 
-223 (861), -47 (70) 
 
 
 
0.003 
PA duration (min/day) 
Exercise (n=23) 
 
61 (97.3) 
 
38 (68) 
 
31 (105), 8 (140) 
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Physical Activity Variables Pre neoadjuvant CRT 
 
Post neoadjuvant CRT  
 
Change, % Change 
 
P value 
Usual care control (n=10) 
   Overall (n=33) 
69 (83) 
64 (80.3) 
50 (4) 
39 (46) 
-34 (151), -41 (52)  
0.45 
Lying down (min/day) 
Exercise (n=23) 
Usual care control (n=10) 
   Overall (n=33) 
 
250 (367.3) 
351.4 (432.4) 
363 (423.9) 
 
360 (351.7) 
541.3 (360.4) 
483.5 (416.5) 
 
6 (211), 2 (40) 
119 (263), 28 (71) 
 
 
 
0.443 
Sleep efficiency (%) 
Exercise (n=7) 
Usual care control (n=7) 
   Overall (n=14) 
 
78 (9.1) 
69 (20) 
75 (11) 
 
78 (13) 
69 (24) 
73 (22) 
 
0.2 (15), 0.3 (21) 
-4 (23), -5 (30) 
 
 
 
0.917 
Sleep duration (min/day) 
Exercise (n=23) 
Usual care control (n=10) 
   Overall (n=33) 
 
220 (330) 
264.5 (284) 
260 (285) 
 
190 (269) 
265 (315) 
44 (318) 
 
0 (141), 0 (35) 
143 (235), 56 (85) 
 
 
 
0.847 
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Physical Activity Variables Pre neoadjuvant CRT 
 
Post neoadjuvant CRT  
 
Change, % Change 
 
P value 
Total EE (kcal/day) 
Exercise (n=23) 
Usual care control (n=10) 
   Overall (n=33) 
 
1668 (932) 
1867 (833) 
1668 (846) 
 
1701 (921) 
1741 (416) 
1707 (722) 
 
-234 (1013), -0.1 (63) 
-241 (1019), 7 (147) 
 
 
 
0.33 
Values presented as median (IQR) for: pre neoadjuvant CRT; post neoadjuvant CRT; change; and % change.  249 
* P<0.05 was taken as statistically significant based on paired Wilcoxon test 250 
All data is averaged over the 72 h period of PA monitoring. Abbreviations: EE – energy expenditure, PA – physical activity.  Note: due to an upgrade in software during data 251 
collection, PAL and sleep efficiency is reported in 7/23 (exercise) and 7/10 (usual care control). 252 
Note: Absolute change (with no brackets) and relative percentage change(in brackets)is reported between pre neoadjuvant CRT (baseline) to post neoadjuvant CRT (week 0) 253 
within the groups. 254 
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Table 3 Changes in physical activity variables (Week 0 - Week 6) 255 
  Exercise  Usual care control  
 
Week 0 
 
Week 3 Week 6 Change, 
% Change 
Week 0 Week 3 Week 6 Change, 
% Change 
P-value 
Step-count 
(steps/day) 
 
3723 (2867) 6333 
(5291) 
5401 
(3869) 
-1544 (5800), 
-22 (52) 
2274 
(3690) 
6422 
(7158) 
4792 
(4370) 
1580 (1732), 
57 (70) 
0.728 
MET 
 
1.3 (0.4) 1.5 (0.4) 1.5 (0.5) -0.1 (0.6), 
-7 (38) 
 
1.1 (0.2) 1.2 (0.3) 1.5 (0.5) 0.2 (2), 
17 (174) 
0.440 
Active EE 
(kcal/day) 
 
152 (154) 355 
(486) 
434 
(658) 
-181 (1228), 
-46 (92) 
244 (198) 322 (517) 392 (701) 320 (1368), 
110 (284) 
0.743 
PA 
duration 
(min/day) 
 
38 (68) 76 (70) 84 (110) -35 (185), 
41 (105) 
39 (46) 66 (89) 89 (132) 85 (243), 
100 (276) 
0.992 
Lying 
down time 
(min/day)*   
 
360 (352) 95 (438) 47 (476) 18 (332), 
4 (82) 
541 (360) 321 (352) 341 (372) 10 (292), 
2 (82) 
0.029 
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  Exercise  Usual care control  
 
Week 0 
 
Week 3 Week 6 Change, 
% Change 
Week 0 Week 3 Week 6 Change, 
% Change 
P-value 
Sleep 
efficiency 
(%)* 
 
78 (13) 78 (14) 80 (15) -6 (28), 
-6 (39) 
69 (24) 66 (14) 76 (20) 6 (11), 
7 (17) 
0.022 
Sleep 
duration 
(min/day)*  
 
190 (265) 405 (70) 369 (81) 0.0 (141), 
1.0 -1.2 (52) 
265 (315) 197 (244) 299 (39) 143 (235), 
3 (112) 
0.028 
Total EE 
(kcal/day) 
 
1707 (921) 1949 
(769) 
1869 
(924) 
-2 (1177), 
-0.1 (63) 
 
1741 (416) 
 
1962 
(730) 
1673 
(1169) 
147 (2705), 
7 (147) 
0.701 
Values presented as median (IQR) for: pre neoadjuvant CRT; post neoadjuvant CRT; change; and % change.  256 
*P<0.05 is taken as statistically significant. All data is averaged over the 72 h period of PA monitoring. Data for each group at each time point is presented.  257 
Note: due to an upgrade in software at the time of data collection, PAL and sleep efficiency is reported in 7/23 (exercise) and 7/10 (usual care control).  258 
Note: Absolute change (no brackets) and relative percentage change (with brackets) at week 6 from baseline ((pre-CRT), presented in table 2)) within the groups. 259 
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Discussion  260 
This pilot study shows that neoadjuvant CRT significantly reduced daily step-count, active EE 261 
and MET in people with newly-diagnosed locally advanced rectal cancer. Furthermore, 262 
neoadjuvant CRT had a generally negative effect on the other exploratory PA variables, 263 
although findings were not statistically significant. People who participated in the 6-week in-264 
hospital exercise training programme, in the time interval following neoadjuvant CRT and prior 265 
to surgery, showed significant improvements in sleep efficiency, sleep duration and lying down 266 
time compared to the usual care control group. Furthermore, the exercise group showed an 267 
improvement in daily step-count and active EE, although these findings did not reach statistical 268 
significance. 269 
It has been previously been reported that neoadjuvant chemo- and chemoradio-therapy 270 
significantly reduce physical fitness and this change is associated with post-operative 271 
complications and reduced 1-year survival in locally advanced rectal and upper gastrointestinal 272 
cancer [2-3].  However, little is known about its effect on PAL and to our knowledge, we are 273 
the first to report daily PAL in people with locally advanced rectal cancer scheduled for 274 
neoadjuvant cancer treatment and surgery.  PAL is commonly quantified by using metabolic 275 
equivalent (MET) which is scored as follows: ≥1.70 (active person); 1.40 – 1.69 276 
(predominantly sedentary); < 1.40 (very inactive); and 1.2 (chair- or bed-bound) [14]. We 277 
reported a MET score at cancer diagnosis 1.3 (0.6) which significantly reduced to 1.2 (0.3) 278 
following neoadjuvant CRT. This MET score suggests that people in our study were sedentary 279 
following neoadjuvant CRT. Although findings were not statistically significant, we reported 280 
lying down time at cancer diagnosis 363 (424) minutes compared to 484 (417). We also 281 
reported, at cancer diagnosis prior to commencing cancer treatment, people in our study had a 282 
lower than recommended daily step-count (7,000 - 10,000)  of 4966 steps (4435) which further 283 
reduced to 3044 steps (3265) following neoadjuvant CRT. Daily step count reported following 284 
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CRT in our study is comparable to daily step count reported in people living with Chronic 285 
Obstructive Pulmonary Disease (COPD) [15]. Although little is known about low levels of PA 286 
in people with cancer, low levels of PA in people with COPD is associated with development 287 
of systemic consequences such as skeletal muscle weakness, osteoporosis, cardiovascular 288 
disease PAL [16] and with hospital admission and mortality [17].  289 
 290 
Participation in the exercise programme had a positive influence on PAL outside the 291 
programme similar to findings reported in other studies in people with breast cancer who 292 
participated in an exercise programme during adjuvant cancer treatment [18-19]. Although 293 
findings were not significant, we reported animprovement in active EE and MET following 294 
participation in the exercise programme initiated following neoadjuvant CRT and before 295 
surgery. We also showed that daily step-count at week 3 following neoadjuvant CRT almost 296 
doubled in both groups compared to week 0 but further reduced at week 6, more so in the usual 297 
care control group (it must be noted, there were no statistical changes in daily step-count 298 
following participation in the exercise programme therefore caution is required while 299 
interpreting our findings). Additionally, following participation in the exercise programme, 300 
there was a significant improvement in sleep efficiency (as well as sleep duration and lying 301 
down time) which may be clinically important: sleep disturbance in people with cancer is the 302 
second most common reported symptom [20]. Sixty-one percent of people with breast cancer 303 
undergoing chemotherapy and radiotherapy report having significant sleep problems 304 
(measured using Pittsburgh Sleep Quality Index) which is related to poor Health Related 305 
Quality of Life (HRQoL) [21]. To our knowledge, only one other study in people with breast 306 
cancer scheduled for multimodal treatment (surgery and adjuvant cancer treatment) has 307 
assessed sleep disturbance in the context of exercise training during cancer treatment 308 
(measured using General Sleep Disturbance response scale) [22]. Although findings from this 309 
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study did not reach statistical significance, there was a decline in sleep disturbance following 310 
a 12-week exercise programme. 311 
To date, measures assessing PAL in people with cancer mainly include subjective self-reported 312 
measures such as: Short Form Health Survey (SF-36) [18, 23-24]; Physical Activity 313 
Questionnaire (PAQ) [23]; Scottish Physical Activity Questionnaire (SPAQ) [18]; and leisure 314 
time physical activity [19], all of which provide a patient’s personal perception of their daily 315 
activities. Such questionnaires have been found to be of limited validity and reliability [25]. 316 
Patients’ estimations of time spent on activities has been shown to be inconsistent when 317 
compared to values recorded using PA monitors [24].  PA monitors have been validated as a 318 
measure of PAL in several patient cohorts such as in people with physical disabilities, COPD 319 
[26-28] and spinal cord injury [29]. PA monitors provide direct measures of specific behaviours 320 
such as steps per day [30] as well as the time spent being active (intensity of activity), standing, 321 
sitting and lying [28]. One recent study reported that cancer patients participating in a lifestyle 322 
intervention during chemotherapy reported 366% higher Moderate-to-Vigorous Intensity PA 323 
(MPVA) using the International PA questionnaire compared to measures collected using 324 
SenseWear accelerometers [31]. Our study highlights that objective measures of PAL 325 
throughout the cancer care journey are worthy of attention: they are relatively simple to 326 
undertake and to date have not been used in the perioperative setting. 327 
 328 
Strengths of this study include its prospective design, the homogenous study population (only 329 
operable locally advanced rectal cancer patients), the clearly defined exercise intervention and 330 
the standardised neoadjuvant CRT regime. PA was averaged over a 72 hour period, measured 331 
in an objective manner using validated Sensewear activity monitors. Furthermore participants 332 
in the exercise group did not wear the PA monitors during exercise sessions. Potential 333 
weaknesses of this study include its design as a relatively small pilot study, which was powered 334 
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to detect changes in objectively measured physical fitness [10], and the limitation of 335 
recruitment to one single centre, which may limit generalisability of results. This was a non-336 
randomised design study (i.e. participants in the usual care control group were people who 337 
were living >15 miles from the hospital) and there was significant baseline differences between 338 
groups in age, ASA and WHO performance status: the usual care control group were older with 339 
poorer subjective performance. Furthermore, differences exist in group sample size, 23/23 340 
(exercise) and 10/16 (usual care control) completed the study. Sleep efficiency data were only 341 
available for 7 in each group: this was due to an upgrade in software during data collection. 342 
 343 
Conclusion 344 
Our study shows that neoadjuvant CRT significantly reduces MET score, active EE and daily 345 
step-count in people with locally advanced rectal. People who participated in a 6-week in-346 
hospital exercise training programme following neoadjuvant CRT showed a significant 347 
improvement in sleep efficiency, sleep duration and lying down time and an apparent 348 
improvement in daily step-count and overall PAL compared to the usual care control group. 349 
 350 
 351 
 352 
 353 
 354 
 355 
 356 
 357 
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FIGURE LEGENDS 496 
 497 
Figure 1. The patient pathway and the time points of assessments.  498 
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